{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:14:28Z","timestamp":1779210868807,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04160-0","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T02:20:28Z","timestamp":1767493228000},"page":"2198-2207","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjuvant anlotinib plus TACE in hepatocellular carcinoma with postoperative high-risk recurrence: a single-arm, multi-center, phase II study"],"prefix":"10.1007","volume":"28","author":[{"given":"Zheng","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kedong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojing","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4796-042X","authenticated-orcid":false,"given":"Zheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"key":"4160_CR1","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450\u201362.","journal-title":"N Engl J Med"},{"key":"4160_CR2","doi-asserted-by":"publisher","first-page":"452","DOI":"10.21037\/hbsn-20-480","volume":"9","author":"DY Xie","year":"2020","unstructured":"Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9:452\u201363.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"4160_CR3","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/med.21775","volume":"41","author":"Q Lu","year":"2021","unstructured":"Lu Q, Guo P, Liu A, Ares I, Martinez-Larranaga MR, Wang X, et al. The role of long noncoding RNA in lipid, cholesterol, and glucose metabolism and treatment of obesity syndrome. Med Res Rev. 2021;41:1751\u201374.","journal-title":"Med Res Rev"},{"key":"4160_CR4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11684-021-0848-3","volume":"15","author":"W Zhang","year":"2021","unstructured":"Zhang W, Zhang B, Chen XP. Adjuvant treatment strategy after curative resection for hepatocellular carcinoma. Front Med. 2021;15:155\u201369.","journal-title":"Front Med"},{"key":"4160_CR5","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402:1835\u201347.","journal-title":"Lancet"},{"key":"4160_CR6","first-page":"3075","volume":"17","author":"MW Welker","year":"2011","unstructured":"Welker MW, Trojan J. Anti-angiogenesis in hepatocellular carcinoma treatment: current evidence and future perspectives. World J Gastroenterol. 2011;17:3075\u201381.","journal-title":"World J Gastroenterol"},{"key":"4160_CR7","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00432-009-0588-2","volume":"135","author":"C Zhong","year":"2009","unstructured":"Zhong C, Guo RP, Li JQ, Shi M, Wei W, Chen MS, et al. A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for stage III A hepatocellular carcinoma. J Cancer Res Clin Oncol. 2009;135:1437\u201345.","journal-title":"J Cancer Res Clin Oncol"},{"key":"4160_CR8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.amjsurg.2008.09.026","volume":"198","author":"BG Peng","year":"2009","unstructured":"Peng BG, He Q, Li JP, Zhou F. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg. 2009;198:313\u20138.","journal-title":"Am J Surg"},{"key":"4160_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s40880-018-0331-y","volume":"38","author":"W Wei","year":"2018","unstructured":"Wei W, Jian PE, Li SH, Guo ZX, Zhang YF, Ling YH, et al. Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety. Cancer Commun. 2018;38:61.","journal-title":"Cancer Commun"},{"key":"4160_CR10","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1158\/1078-0432.CCR-17-2899","volume":"24","author":"Z Wang","year":"2018","unstructured":"Wang Z, Ren Z, Chen Y, Hu J, Yang G, Yu L, et al. Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study. Clin Cancer Res. 2018;24:2074\u201381.","journal-title":"Clin Cancer Res"},{"key":"4160_CR11","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.hpb.2019.12.013","volume":"22","author":"W Chen","year":"2020","unstructured":"Chen W, Ma T, Zhang J, Zhang X, Chen W, Shen Y, et al. A systematic review and meta-analysis of adjuvant transarterial chemoembolization after curative resection for patients with hepatocellular carcinoma. HPB (Oxford). 2020;22:795\u2013808.","journal-title":"HPB (Oxford)"},{"key":"4160_CR12","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1080\/00365521.2017.1292365","volume":"52","author":"M Liao","year":"2017","unstructured":"Liao M, Zhu Z, Wang H, Huang J. Adjuvant transarterial chemoembolization for patients after curative resection of hepatocellular carcinoma: a meta-analysis. Scand J Gastroenterol. 2017;52:624\u201334.","journal-title":"Scand J Gastroenterol"},{"key":"4160_CR13","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ejso.2012.01.006","volume":"38","author":"JH Zhong","year":"2012","unstructured":"Zhong JH, Li H, Li LQ, You XM, Zhang Y, Zhao YN, et al. Adjuvant therapy options following curative treatment of hepatocellular carcinoma: a systematic review of randomized trials. Eur J Surg Oncol. 2012;38:286\u201395.","journal-title":"Eur J Surg Oncol"},{"key":"4160_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/COC.0000000000000619","volume":"43","author":"J Huang","year":"2020","unstructured":"Huang J, Liu FC, Li L, Yuan SX, Yang Y, Jiang BG, et al. Prognostic nomogram for Hepatitis B virus-related hepatocellular carcinoma with adjuvant transarterial chemoembolization after radical resection. Am J Clin Oncol. 2020;43:20\u20137.","journal-title":"Am J Clin Oncol"},{"key":"4160_CR15","doi-asserted-by":"publisher","first-page":"8635","DOI":"10.1158\/0008-5472.CAN-08-0917","volume":"68","author":"I Ader","year":"2008","unstructured":"Ader I, Brizuela L, Bouquerel P, Malavaud B, Cuvillier O. Sphingosine kinase 1: a new modulator of hypoxia inducible factor 1\u03b1 during hypoxia in human cancer cells. Cancer Res. 2008;68:8635\u201342.","journal-title":"Cancer Res"},{"key":"4160_CR16","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/j.1572-0241.2007.01712.x","volume":"103","author":"A Sergio","year":"2008","unstructured":"Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol. 2008;103:914\u201321.","journal-title":"Am J Gastroenterol"},{"key":"4160_CR17","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1200\/JCO.2023.41.4_suppl.493","volume":"41","author":"M Kuang","year":"2023","unstructured":"Kuang M, Peng Z, Fan W, Liu Z, Xiao H, Tu J, et al. Adjuvant transarterial chemoembolization with sorafenib for patients with hepatocellular carcinoma with portal vein tumor thrombus after surgery: a phase III, multicenter, randomized, controlled trial. J Clin Oncol. 2023;41:493.","journal-title":"J Clin Oncol"},{"key":"4160_CR18","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.hbpd.2025.03.001","volume":"24","author":"JH Chen","year":"2025","unstructured":"Chen JH, Lu L, Zhang XY, Xiang BD, Xu X, Li XC, et al. Adjuvant lenvatinib in combination with transarterial chemoembolization for hepatocellular carcinoma patients with high risk of postoperative recurrence: a multicenter prospective cohort study. Hepatobiliary Pancreat Dis Int. 2025;24:277\u201385.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"4160_CR19","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40265-018-0939-x","volume":"78","author":"YY Syed","year":"2018","unstructured":"Syed YY. Anlotinib: first Global Approval. Drugs. 2018;78:1057\u201362.","journal-title":"Drugs"},{"key":"4160_CR20","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","volume":"11","author":"G Shen","year":"2018","unstructured":"Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11:120.","journal-title":"J Hematol Oncol"},{"key":"4160_CR21","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1016\/j.bbrc.2018.08.098","volume":"503","author":"C He","year":"2018","unstructured":"He C, Wu T, Hao Y. Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway. Biochem Biophys Res Commun. 2018;503:3093\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"4160_CR22","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41419-020-02749-7","volume":"11","author":"F Song","year":"2020","unstructured":"Song F, Hu B, Cheng J-W, Sun Y-F, Zhou K-Q, Wang P-X, et al. Anlotinib suppresses tumor progression via blocking the VEGFR2\/PI3K\/AKT cascade in intrahepatic cholangiocarcinoma. Cell Death Dis. 2020;11:573.","journal-title":"Cell Death Dis"},{"key":"4160_CR23","doi-asserted-by":"publisher","first-page":"v288","DOI":"10.1093\/annonc\/mdz247.077","volume":"30","author":"A Zhou","year":"2019","unstructured":"Zhou A, Sun Y, Zhang W, Jiang Z, Chen B, Zhao J, et al. 751P - Anlotinib for advanced hepatocellular carcinoma: interim results from the phase II ALTER0802 study. Ann Oncol. 2019;30:v288\u20139.","journal-title":"Ann Oncol"},{"key":"4160_CR24","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/2211-5463.13102","volume":"11","author":"Y Hong","year":"2021","unstructured":"Hong Y, Feng Y, Sun H, Zhang B, Wu H, Zhu Q, et al. Tislelizumab uniquely binds to the CC\u2032 loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage. FEBS Open Bio. 2021;11:782\u201392.","journal-title":"FEBS Open Bio"},{"key":"4160_CR25","doi-asserted-by":"publisher","first-page":"153303382096558","DOI":"10.1177\/1533033820965587","volume":"19","author":"W Guo","year":"2020","unstructured":"Guo W, Chen S, Wu Z, Zhuang W, Yang J. Efficacy and safety of transarterial chemoembolization combined with anlotinib for unresectable hepatocellular carcinoma: a retrospective study. Technol Cancer Res Treat. 2020;19:1533033820965587.","journal-title":"Technol Cancer Res Treat"},{"key":"4160_CR26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52\u201360.","journal-title":"Semin Liver Dis"},{"key":"4160_CR27","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","volume":"56","author":"EASL-EORTC clinical practice guidelines","year":"2012","unstructured":"EASL-EORTC clinical practice guidelines. Management of hepatocellular carcinoma. J Hepatol. 2012;56:908\u201343.","journal-title":"J Hepatol"},{"key":"4160_CR28","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.3748\/wjg.v11.i23.3644","volume":"11","author":"HY Cheng","year":"2005","unstructured":"Cheng HY, Wang X, Chen D, Xu AM, Jia YC. The value and limitation of transcatheter arterial chemoembolization in preventing recurrence of resected hepatocellular carcinoma. World J Gastroenterol. 2005;11:3644\u20136.","journal-title":"World J Gastroenterol"},{"key":"4160_CR29","doi-asserted-by":"publisher","first-page":"S1230","DOI":"10.1016\/j.annonc.2024.08.2279","volume":"35","author":"A Yopp","year":"2024","unstructured":"Yopp A, Kudo M, Chen M, Cheng AL, Kaseb AO, Lee HC, et al. LBA39 updated efficacy and safety data from IMbrave050: phase III study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC). Ann Oncol. 2024;35:S1230.","journal-title":"Ann Oncol"},{"key":"4160_CR30","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1097\/HEP.0000000000000726","volume":"82","author":"A Vogel","year":"2025","unstructured":"Vogel A, Grant RC, Meyer T, Sapisochin G, O\u2019Kane GM, Saborowski A. Adjuvant and neoadjuvant therapies for hepatocellular carcinoma. Hepatology. 2025;82:777\u201393.","journal-title":"Hepatology"},{"key":"4160_CR31","doi-asserted-by":"publisher","first-page":"957","DOI":"10.4254\/wjh.v8.i23.957","volume":"8","author":"JH Zhong","year":"2016","unstructured":"Zhong JH, Du XK, Xiang BD, Li LQ. Adjuvant sorafenib in hepatocellular carcinoma: a cautionary comment of STORM trial. World J Hepatol. 2016;8:957\u201360.","journal-title":"World J Hepatol"},{"key":"4160_CR32","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","volume":"16","author":"J Bruix","year":"2015","unstructured":"Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344\u201354.","journal-title":"Lancet Oncol"},{"key":"4160_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","volume":"654","author":"B Lin","year":"2018","unstructured":"Lin B, Song X, Yang D, Bai D, Yao Y, Lu N. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFR\u03b2 and FGFR1. Gene. 2018;654:77\u201386.","journal-title":"Gene"},{"key":"4160_CR34","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.23131","volume":"122","author":"J Matsui","year":"2008","unstructured":"Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008;122:664\u201371.","journal-title":"Int J Cancer"},{"key":"4160_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13045-019-0718-5","volume":"12","author":"S Qin","year":"2019","unstructured":"Qin S, Li A, Yi M, Yu S, Zhang M, Wu K. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol Oncol. 2019;12:27.","journal-title":"J Hematol Oncol"},{"key":"4160_CR36","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2016.5059","volume":"152","author":"K Sasaki","year":"2017","unstructured":"Sasaki K, Shindoh J, Margonis GA, Nishioka Y, Andreatos N, Sekine A, et al. Effect of background liver cirrhosis on outcomes of hepatectomy for hepatocellular carcinoma. JAMA Surg. 2017;152:e165059.","journal-title":"JAMA Surg"},{"key":"4160_CR37","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ijsu.2019.08.033","volume":"71","author":"E Bl\u00fcthner","year":"2019","unstructured":"Bl\u00fcthner E, Bednarsch J, Malinowski M, Binder P, Pratschke J, Stockmann M, et al. Dynamic liver function is an independent predictor of recurrence-free survival after curative liver resection for HCC - a retrospective cohort study. Int J Surg. 2019;71:56\u201365.","journal-title":"Int J Surg"},{"key":"4160_CR38","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1200\/JCO.2000.18.5.1094","volume":"18","author":"RT Poon","year":"2000","unstructured":"Poon RT, Fan ST, Lo CM, Liu CL, Ng IO, Wong J. Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. J Clin Oncol. 2000;18:1094\u2013101.","journal-title":"J Clin Oncol"},{"key":"4160_CR39","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1002\/hep.27290","volume":"60","author":"M Kudo","year":"2014","unstructured":"Kudo M, Han G, Finn RS, Poon RTP, Blanc J-F, Yan L, et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial. Hepatology. 2014;60:1697\u2013707.","journal-title":"Hepatology"},{"key":"4160_CR40","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s12072-021-10184-9","volume":"15","author":"Z Fu","year":"2021","unstructured":"Fu Z, Li X, Zhong J, Chen X, Cao K, Ding N, et al. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study. Hepatol Int. 2021;15:663\u201375.","journal-title":"Hepatol Int"},{"key":"4160_CR41","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1158\/1078-0432.CCR-17-3766","volume":"24","author":"Y Chi","year":"2018","unstructured":"Chi Y, Fang Z, Hong X, Yao Y, Sun P, Wang G, et al. Safety and efficacy of Anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma. Clin Cancer Res. 2018;24:5233\u20138.","journal-title":"Clin Cancer Res"},{"key":"4160_CR42","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E","volume":"56","author":"K Okuda","year":"1985","unstructured":"Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients. Cancer. 1985;56:918\u201328.","journal-title":"Cancer"},{"key":"4160_CR43","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/hep.26120","volume":"57","author":"A Duffy","year":"2013","unstructured":"Duffy A, Wilkerson J, Greten TF. Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies. Hepatology. 2013;57:1068\u201377.","journal-title":"Hepatology"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04160-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04160-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04160-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:03:25Z","timestamp":1779210205000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04160-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["4160"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04160-0","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of the First Affiliated Hospital of Xi\u2019an Jiaotong University [No. XJTU1AF2019LSK-211] and the First Hospital of Lanzhou University [No. 2020\u201330]. All procedures in the present study conformed to the ethical standards of the institutional and\/or national research committee, Good Clinical Practice guidelines, and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Ethical approval and consent were obtained from the participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients provided informed consent for the publication of any associated data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}